Effects of Anti-VEGF Targeted Drugs on Patients' Blood Pressure and Endothelial Function

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04962438

Enrollment

Registered

2021-07-15

Start date

2019-07-05

Completion date

2021-12-30

Last updated

2021-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Toxicity, VEGF, Endothelial Dysfunction

Keywords

Cardiac safety, anti-VEGF drugs, Endothelial dysfunction

Brief summary

Explore the effects of anti-VEGF targeted drugs on blood pressure and endothelial function in cancer patients.

Detailed description

Thirty tumor patients with anti-VEGF drugs were selected. Demographic information and clinical information of all patients were collected before chemotherapy. Ambulatory blood pressure monitoring and endothelial function measurement (PWV, EndoPAT) were performed. Ambulatory blood pressure and PWV were reviewed at 2 weeks and 1 month. And EndoPAT, to evaluate the effects of anti-VEGF drugs on blood pressure and endothelial function in cancer patients.

Interventions

DRUGAnti-VEGF

Anti-tumor drugs targeting the vascular endothelial growth factor (VEGF) signaling pathway

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Tumor patients using anti-VEGF drugs

Exclusion criteria

* Hypertension, coronary heart disease, valvular heart disease, cardiomyopathy and other organic heart diseases, exclude liver and kidney failure, severe cerebrovascular disease, chronic obstructive pulmonary disease, rheumatic immune system disease

Design outcomes

Primary

Measure	Time frame	Description
Time ending	1 month	30 days after using the Anti-VEGF Targeted Drugs

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026